comparemela.com

Latest Breaking News On - Presented february - Page 1 : comparemela.com

How to Help Pediatricians Apply Peanut Allergy Guidelines

New training and EHR support tool could help busy pediatric clinicians identify high-risk infants and implement latest feeding guidelines.

United statesSan antonioChapel hillRuchi guptaJonathan nechelesEdwin kimBelhaven biopharmaUkko incNational institute of allergyUniversity of north carolinaYobee care incAllergy therapeutics ltdFood allergy researchKenota healthFood allergy research educationNational institutes of health

Epinephrine Nasal Spray Making Headway

Needle-free alternatives to epinephrine autoinjectors are showing promising results.

United statesSan antonioDavid dworaczykBrian schroerRichard lowenthalAmerican academy of allergyAmerican academyBryn pharmaNew drug applicationAquestive therapeuticsCleveland clinicMedscape medicalPresented februaryFood allergyDrug delivery systemPeer review

Needle-Free Epinephrine Products Could Be Available in 2023

Companies are developing needle-free formulations of epinephrine, including several nasal sprays and a sublingual film.

United statesRutgers universityNew jerseyNorth carolinaSan diegoPharma raleighJohn oppenheimerRichard lowenthalKeith kendallDavid stukusRutgers university school of medicinePharmaceuticals san diegoAmerican academy of allergyAmerican academyBryn pharmaAquestive therapeutics

Asthma: Easy Strategy Reduces Exacerbations, Improves Control

Black and Latino asthma patients who self-administered inhaled steroids each time they used rescue medication reduced their annual rate of asthma attacks by 15% in a phase 4 trial.

United statesBrian vickeryJuan carlos cardetUniversity of south floridaNational institute of allergyFood allergy center at emory universityCircassia pharmaceuticalsAmerican academy of allergyTeva pharmaceuticalsAmerican lung associationOutcomes research instituteLate breaking oral abstractsAmerican academyNew england journalCarlos cardetSouth florida

PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer

Two new trials exploring this approach ― olaparib in the PROpel trial and niraparib in the MAGNITUDE trial –― had slightly different results.

United kingdomBritish columbiaFred saabKimn chiUniversity of british columbiaDepartment of urologic sciencesVancouver prostate centerUniversity of montreal hospital centerDepartment of medicineGenitourinary cancers symposiumMontreal hospital centerUrologic sciencesCancers symposiumPresented februaryMetastatic and advanced prostate cancerClinical research

vimarsana © 2020. All Rights Reserved.